Business

Fredun Pharmaceuticals Expands Manufacturing Base with Fifth Facility at Palghar

Apr 29, 2026

PNN
Mumbai (Maharashtra) [India], April 29: Fredun Pharmaceuticals Limited (BSE - FREDUN | 539730), one of India's leading pharmaceutical formulation manufacturing companies with a diversified presence across generics, cosmeceuticals, nutraceuticals, mobility, and animal healthcare products, has announced the establishment of a new manufacturing facility in Palghar, Maharashtra, marking the addition of its fifth facility.
Manufacturing Expansion Highlights
- 40,000 sq. ft. New Facility Added
Marks a significant step in the Company's expansion journey; expected to be operational by October 2026.
- 50,000 sq. ft. Planned Expansion
To be undertaken under strategic growth initiatives.
- Supports Key Product Categories
Veterinary products, supportive nutraceuticals, and pharmaceutical formulations.
- Expected Operational Benefits
Enhanced efficiency, improved production scalability, and the ability to meet growing domestic and international demand.
- Stronger Manufacturing Footprint
Integration with existing facilities strengthens presence across the pharmaceutical and nutraceutical sectors.
The Company remains committed to maintaining high standards of quality, compliance, and innovation while strengthening its position as a leading manufacturing partner in the healthcare industry.
Commenting on the development, Mr. Fredun Medhora, Managing Director, said: "As our business continues to expand, we are gradually strengthening our manufacturing footprint to stay aligned with our requirements. With opportunities opening up across our key segments, our focus remains on building a stronger and more scalable foundation."
(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same.)

More news

STL delivers resilient FY'26 performance; AI Data Centre business emerges as key growth engine

Mumbai (Maharashtra) [India], April 29: STL (NSE: STLTECH), a leading connectivity solutions provider for AI-ready digital infrastructure, today announced its financial results for the year ended 31 March, 2026. The Company reported revenues of INR 1,441 Cr for the quarter and INR 4,745 Cr for FY26, a growth of ~14.7% QoQ and 18.8% YoY. In FY26, STL delivered EBITDA margins at ~13.2% and EBITDA of INR 628 Cr. The year was characterised by a transformative ~110% surge in order intake over FY25. This indicates strong revenue visibility and sets the stage for sustained growth in the coming quarters.

Apr 29, 2026